Solexa named Brock Siegel as chief operating officer last week.
Siegel spent the last 15 years with Applied Biosystems in a variety of senior management positions. Most recently he was vice president of quality and process excellence. Prior to ABI he was at Millipore and Henkel Research.
Siegel was a professor of bioorganic chemistry and chemical engineering at the University of Minnesota and did his postdoc at Columbia University. He received a PhD from the University of Illinois and a BS in chemistry from Syracuse University.
The US Food and Drug Administration has appointed Mark Goldberger as medical director for emerging and pandemic threat preparedness in its Center for Biologics Evaluation and Research.
He will join the center full-time at the end of August.
Goldberger will serve as a senior advisor to CBER's pandemic flu program, be a part of its senior leadership team, and chair the Pandemic Influenza Steering Committee.
Goldberger came to the agency in 1989 as a medical reviewer, and currently serves as the director of the Office of Antimicrobial Products in the Center for Drug Evaluation and Research.
He completed his residency and fellowship in infectious diseases at Columbia University after receiving his MD from the university. He also served as an Epidemic Intelligence Service Officer at the Centers for Disease Control and Prevention.
Decode Genetics appointed Earl Collier to its board of directors, the company said last week.
Collier is an executive vice president at Genzyme and has previously served as president of Vitas Healthcare. He was a partner at the law firm Hogan and Hartson. He was also a deputy administrator of the Health Care Finance Administration in the Department of Health and Human Services.
Collier received his BA from Yale University and his JD from the University of Virginia.